| Edition |
1. Aufl. |
| Description |
1 online resource (85 pages). |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
|
data file rda |
| Series |
MIPLC studies ; v. 20 |
|
MIPLC studies ; v. 20.
|
| Bibliography |
Includes bibliographical references. |
| Contents |
Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices. |
|
F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German. |
|
Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others. |
| Summary |
Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20. |
| Note |
Online resource; title from digital title page (viewed on Apr. 25, 2014). |
| Subject |
Drugs -- Patents.
|
|
Médicaments -- Brevets d'invention.
|
|
LAW / Commercial / General
|
|
Drugs. (OCoLC)fst00898761
|
| Genre/Form |
Electronic books.
|
|
Electronic books.
|
|
Patents. (OCoLC)fst01423842
|
| Other Form: |
Print version: Donghi, Monica. Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? Baden-Baden : Nomos Verlagsgesellschaft, ©2014 9783848709915 |
| ISBN |
9783845251288 |
|
384525128X |
|
9783848709915 |
|
3848709910 |
| Standard No. |
DEBSZ 431647895 |
|
AU@ 000062534616 |
|
AU@ 000056062506 |
|
